A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Hypercholesterolemia

In brief

To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.

Key facts

Study ID

NCT07634484

Run by

Kowa Company, Ltd.

People needed

120

Starts

2026-07-01

Expected to finish

2027-07-31

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NTT Medical Center Sapporo — Hokkaido, Japan (enrolling)
• Ami Higashi Clinic — Ibaraki, Japan (enrolling)
• Olive Takamatsu Medical Clinic — Kagawa, Japan (enrolling)
• Medical Corporation Shintokai Yokohama Minoru Clinic — Kanagawa, Japan (enrolling)
• Medical Corporation Heishinkai OCROM Clinic — Osaka, Japan (enrolling)
• Hirose Clinic — Saitama, Japan (enrolling)
• Medical Corporation Yukeikai Asano Internal Medicine Clinic — Saitama, Japan (enrolling)
• Medical Corporation Asbo Tokyo Asbo Clinic — Tokyo, Japan (enrolling)
• Medical Corporation Heishinkai ToCROM Clinic — Tokyo, Japan (enrolling)
• Shimokitazawa Tomo Clinic — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.